Assessment of patient-reported outcomes of insulin pen devices versus conventional vial and syringe

Diabetes Technology and Therapeutics

Volumn 11, Issue 8, 2009, Pages 529-538

  Molife, Cliff ^a   Lee, Lauren J ^a   Shi, Lizheng ^b   Sawhney, Monika ^b   Lenox, Sheila M ^a  

^a ELI LILLY AND COMPANY   (United States)

^b TULANE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN;

ADULT; ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; FEMALE; FOLLOW UP; HUMAN; INFORMATION RETRIEVAL; INJECTION PAIN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN PEN; INSULIN TREATMENT; INSULIN VIAL; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PAIN ASSESSMENT; PATIENT CARE; PATIENT COMPLIANCE; PATIENT SATISFACTION; PRIORITY JOURNAL; PUBLICATION; QUALITY OF LIFE; SCREENING; SELF CARE; SYRINGE;

ADOLESCENT; ADULT; AGED; CHILD; CONSUMER SATISFACTION; DIABETES MELLITUS; EQUIPMENT DESIGN; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; NEEDLES; PATIENTS; SYRINGES; YOUNG ADULT;

EID: 70349462535     PISSN: 15209156     EISSN: None     Source Type: Journal    
DOI: 10.1089/dia.2009.0007     Document Type: Article

References (62)

1. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993;329:977-986.
2. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. UK Prospective Diabetes Study Group. UK Prospective Diabetes Study (UKPDS) 33. Lancet 1998;352:837-853.
3. Oglesby AK, Secnik K, Barron J, Al Zakwani I, Lage MJ: The association between diabetes related medical costs and glycemic control: A retrospective analysis. Cost Eff Resour Alloc 2006;4:1.
4. Norris SL, Lau J, Smith SJ, Schmid CH, Engelgau MM: Selfmanagement education for adults with type 2 diabetes: A meta-analysis of the effect on glycemic control. Diabetes Care 2002;25:1159-1171.
5. Spellman CW: Insulin therapy for maximal glycemic control in type 2 diabetes mellitus. J Am Osteopath Assoc 2007; 107:260-269.
6. Hunt LM, Valenzuela MA, Pugh JA: NIDDM patients' fears and hopes about insulin therapy: The basis of patient reluctance. Diabetes Care 1997;20:292-298.
7. Da Costa S, Brackenridge B, Hicks DA: Comparison of insulin pen use in the United States and the United Kingdom. Diabetes Educ 2002;28:52-60.
8. Korytkowski M, Niskanen L, Asakura T: FlexPen: Addressing issues of confidence and confidence and convenience in insulin delivery. Clin Ther 2005;27(Suppl B):S89-S100.
9. Rex J, Jensen KH, Lawton SA: A review of 20 years' experience with the NovoPen family of insulin injection devices. Clin Drug Invest 2006;26:367-401.
10. Fleming DR: Mightier than the syringe. Am J Nurs 2000; 100(11):44-48.
11. Flood T: Advances in insulin delivery systems and devices: Beyond the vial and syringe. Insulin 2006;1:99-108.
12. Funnell MM: Quality of life and insulin therapy in type 2 diabetes mellitus. Insulin 2008;3:31-36.
13. Piscopo MA, Chiesa G, Bonfanti R, Viscardi M, Meschi F, Chiumello G: Quality of life and new devices in the management of type 1 diabetes in children and adolescents. Acta Biomed 2003;74(Suppl 1):21-25.
14. Albano S: Assessment of quality of treatment in insulintreated patients with diabetes using a pre-filled insulin pen. The ORBITER Study Group. Acta Biomed 2004;75:34-39.
15. Anderson DM, Barnett AH: A multicenter study of B-D (Becton Dickinson) pen as a delivery system for human insulin. Pract Diabetes 1994;11:36-38.
16. Anderson PO, Wikby A: Pen injection and change in metabolic control and quality of life in insulin dependent diabetes mellitus. Diabetes Res Clin Pract 1997;36:169-172.
17. Arslanoglu I, Saka N, Bundak R, Gunoz H, Darendeliler F: A comparison of the use of premixed insulins in pen-injectors with conventional patient-mixed insulin treatment in children and adolescents with IDDM. Is there a decreased risk of night hypoglycemia? J Pediatr Endocrinol Metab 2000;13: 313-318.
18. Barnett AH, Bowen JD, Burden AC: Multicentre study to assess quality of life and glycaemic control of type 2 diabetic patients treated with insulin compared with oral hypoglycaemic agents. Pract Diabetes Int 1996;13:179-183.
19. Berger AS, Saurbrey N, Kuhl C, Villumsen J: Clinical experience with a new device that will simplify insulin injections. Diabetes Care 1985;8:73-76.
20. Bohannon NJV, Ohannesian JP: Patient and physician satisfaction with the HUMULIN/HUMALOG Pen, a new 3.0mL prefilled pen device for insulin delivery. Clin Ther 2000;22:1049-1067.
21. Buysschaert M, Janne P, Mpoy M, Reynaert C, Pirson F, Cassiers L, Lambert AE: Metabolic and psychological evolution of insulin dependent diabetic patients during a 6 months insulin-pen treatment. Diabetes Metab 1988;14: 75-79.
22. Chantelau E, Schiffers T, Schutze J, Hansen B: Effect of patient-selected intensive insulin therapy on quality of life. Patient Educ Couns 1997;30:167-173.
23. Chen HS, Hwu CM, Ching FK, Kwok CF, Yang HJ, Shih KC, Lin BJ, Ho LT: Clinical response and patient acceptance of a prefilled, disposable insulin pen injector for insulintreated diabetes. Zhonghua Yi Xue Za Zhi (Taipei) 1999;62: 455-460.
24. Corsi A, Torre E, Coronel G, Ghisoni G, Carboni G, De Castro A, Comaschi M: Pre-filled insulin pen in newly insulin-treated diabetic patients over 60 years old. Diabetes Nutr Metabol Clin Exp 1997;10:78-81.
25. Coscelli C, Lostia S, Lunetta M, Nosari I, Coronel GA: Safety, efficacy, acceptability of a pre-filled insulin pen in diabetic patients over 60 years old. Diabetes Res Clin Pract 1995; 28:173-177.
26. Dunbar JM, Madden PM, Gleeson DT, Fiad TM, McKenna TJ: Premixed insulin preparations in pen syringes maintain glycemic control and are preferred by patients. Diabetes Care 1994;17:874-878.
27. Engstrom LHK: Insulin pen for administration of isophane insulin. Pract Diabetes 1990;7:162-164.
28. Fox C, McKinnon C, Wall A, Simon AL: Ability to handle, and patient preference for, insulin delivery devices in visually impaired patients with type 2 diabetes. Pract Diabetes Int 2002;19:104-107.
29. Graff MR, McClanahan MA: Assessment by patients with diabetes mellitus of two insulin pen delivery systems versus a vial and syringe. Clin Ther 1998;8:486-496.
30. Hanas R, Ludvigsson J: Experience of pain from insulin injections and needle phobia in young patients with IDDM. Pract Diabetes Int 1997;14:95-99.
31. Houtzagers CM, Visser AP, Berntzen PA, van der Stap H, van Maarschalkerweerd WW, Heine RJ, van der Veen EA: Multiple daily insulin injections improve self-confidence. Diabet Med 1989;6:512-519.
32. Houtzagers CM, Berntzen PA, van der Stap H, van Maarschalkerweerd WW, Lanting P, Boen Tan I, Heine RJ, van der Veen EA: Efficacy and acceptance of two intensified conventional insulin therapy regimens: A long-term crossover comparison. Diabetes Med 1989;6:416-421.
33. Hung CT, Wang FF: Pen injector for insulin-requiring diabetic patients. J Formos Med Assoc 1992;91:1026-1029.
34. Jorgensen J, Flyvbjerg A, Jorgensen JT, Sorensen SS, Johansen BR, Christiansen JS: NPH insulin administration by means of a pen injector. Diabet Med 1988;5:574-576.
35. Kadiri A, Chraibi A, Marouan F, Ababou MR, El Guermai N, Wadjinny A, Kerfati A, Douiri M, Bensouda JD, Belkhadir J, Arvanitis Y: Comparison of NovoPen 3 and syringes/vials in the acceptance of insulin therapy in NIDDM patients with secondary failure to oral hypoglycaemic agents. Diabetes Res Clin Pract 1998;41:15-23.
36. Kolendorf K, Beck-Nielsen H, Oxenboll B: Clinical experience with NovoPen II and insulin Protaphane HM Penfill. Postgrad Med J 1988;64(Suppl 3):14-16.
37. Korytkowski M, Bell D, Jacobsen C, Suwannasari R: A multicenter, randomized, open-label, comparative, twoperiod crossover trial of preference, efficacy, and safety profiles of a prefilled, disposable pen and conventional vial/ syringe for insulin injection in patients with type 1 or 2 diabetes mellitus. Clin Ther 2003;25:2836-2848.
38. Martin JM, Llewelyn JA, Ristic S, Bates PC: Acceptability and safety of a new 3.0ml re-usable insulin pen (HumaPen) in clinical use. Diabetes Nutr Metab Clin Exp 1999;12:306-309.
39. Murray DP, Keenan P, Gayer E, Salmon P, Tomkin GH, Drury MI, O'Sullivan DJ: A randomized trial of the efficacy and acceptability of a pen injector. Diabet Med 1988;5:750-754.
40. O'Hagan M, Greene SA: Pre-mixed insulin delivered by disposable pen in the management of children with diabetes. Diabet Med 1993;10:972-975.
41. Rowe BR, Pizzey M, Barnett AH: A clinical evaluation of the B-D pen. Pract Diabetes 1992;9:138-139.
42. Rubin RR, Peyrot M: Factors affecting use of insulin pens by patients with type 2 diabetes. Diabetes Care 2008;31:430-431.
43. Saurbrey N, Berger A, Kuhl C: The NovoPen: A practical tool for simplifying multiple injection insulin therapy. Acta Paediatr Scand Suppl 1985;320:64-65.
44. Schuster MW, Chauhan SP, McLaughlin BN, Perry KG, Morrison JC: Comparison of insulin regimens and administration modalities in pregnancy complicated by diabetes. J Miss State Med Assoc 1998;39:208-212.
45. Schwartz S, Khutoryansky N, Braceras R: Comparison of resource utilisation, preference and handling of a pre-filled pen and vial/syringe in patients with type 2 diabetes mellitus. J Clin Res 2007;10:1-10.
46. Shelmet J, Schwartz S, Cappleman J, Peterson G, Skovlund S, Lytzen L, Nicklasson L, Liang J, Lyness W; InnoLet® Study Group: Preference and resource utilization in elderly patients: InnoLet® versus vial/syringe. Diabetes Res Clin Pract 2003;63:27-35.
47. Small M, MacRury S, Boal A: Comparison of conventional twice daily subcutaneous insulin administration and a multiple injection regimen (using the NovoPen) in insulindependent diabetes mellitus. Diabet Res 1988;8:85-89.
48. Spijker AJ, Hoekstra JBL, Erkelens DW: The insulin pen: A new device for multiple insulin injections. Transplant Proc 1986;18:1689-1690.
49. Stockl K, Ory C, Vanderplas A, Nicklasson L, Lyness W, Cobden D, Chang E: An evaluation of patient preference for an alternative insulin delivery system compared to standard vial and syringe. Curr Med Res Opin 2007;23:133-146.
50. Stocks A: Huma Pen Ergo: A new 3.0ml reusable insulin pen evaluation of patient acceptability. Clin Drug Investig 2001;21:319-324.
51. Sucic M, Galic E, Cabrijan T, Ivandic A, Petrusic A, Wyatt J, Mincheva N, Milicevic Z, Malone J: Patient acceptance and reliability of new Humulin/Humalog 3.0 ml prefilled insulin pen in ten Croatian diabetes centers. Med Sci Monit 2002;8:P121-P126.
52. Tallroth G, Karlson B, Nilsson A, Agardh CD: The influence of different insulin regimens on quality of life and metabolic control in insulin-dependent diabetics. Diabetes Res Clin Pract 1989;6:37-43.
53. Wikby A, Stenstrom U, Andersson PO, Hörnquist J: Metabolic control, quality of life, and negative life events: A longitudinal study of well-controlled and poorly regulated patients with type 1 diabetes after changeover to insulin pen treatment. Diabetes Educ 1998;24:61-66.
54. Wilk T, Mora PF, Chaney S, Shaw K: Use of an insulin pen by homeless patients with diabetes mellitus. J Am Acad Nurse Pract 2002;14:372-379.
55. Ignaut DA, Opincar M, Lenox S: FlexPen® and KwikPen™ prefilled insulin devices: A laboratory evaluation of ergonomic and injection force characteristics. J Diabetes Sci Technol 2008;2:533-537.
56. Lawton SA: A Practical Guide to Insulin Injection. A Resource for Diabetes Educators. Bagsværd, Denmark: Novo Nordisk A/S, 2000.
57. Newman KD, Weaver MT: Insulin measurement and preparation among diabetic patients at a county hospital. Nurse Pract 1994;19:44-45, 48.
58. Coscelli C, Calabrese G, Fedele D, Pisu E, Calderini C, Bistoni S, Lapolla A, Mauri MG, Rossi A, Zappella A: Use of premixed insulin among the elderly. Reduction of errors in patient preparation of mixtures. Diabetes Care 1992;15:1628-1630.
59. National Diabetes Fact Sheet: General Information and National Estimate in the United States, 2007. Atlanta: Centers for Disease Control and Prevention, 2008.
60. Vijan S, Hayward RA, Ronis DL, Hofer TP: The burden of diabetes therapy implications for the design of effective patient-centered treatment regimens. J Gen Intern Med 2005;20:479-482.
61. Becker MH, Malman LA: Sociobehavioral determinants of compliance with health and medical care recommendations. Med Care 1975;13:10-24.
62. Rosenstock IM: The health belief model and preventive health behavior. Health Educ Monogr 1974;2:354-386.